Paper36089112
Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection.
Hu Y and 21 others. Bioorg Med Chem Lett, 2022. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection. Papers, record 36089112. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36089112
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B | Major topic |
| Hepatitis B, Chronic | Major topic |
| Animals | |
| Rats | |
| Antigens, Surface | |
| Antiviral Agents | |
| DNA, Viral | |
| Hepatitis B e Antigens | |
| Hepatitis B Surface Antigens | |
| Hepatitis B virus | |
| Benzoxepins | |
| Pyridines |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04499443 | Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets | Derived from the trial | Yes |
Source ClinicalTrials.gov
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42865026 | Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study. | Liver Int | 2026 | https://conductscience.org/library/papers/42865026 | PubMed |
| 42281419 | KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA). | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/42281419 | PubMed |
| 41754527 | Direct Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies. | Viruses | 2026 | https://conductscience.org/library/papers/41754527 | PubMed |
| 38543689 | Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161. | Viruses | 2024 | https://conductscience.org/library/papers/38543689 | PubMed |
| 38428537 | "PROTAC" modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro. | Bioorg Med Chem Lett | 2024 | https://conductscience.org/library/papers/38428537 | PubMed |
| 37755289 | The Battle for Survival: The Role of RNA Non-Canonical Tails in the Virus-Host Interaction. | Metabolites | 2023 | https://conductscience.org/library/papers/37755289 | PubMed |
| 37009498 | The progress of molecules and strategies for the treatment of HBV infection. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37009498 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36089112
GET https://conductscience.org/api/papers/v1/36089112/authors?page=2